A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis

Authors

  • F. Ashtari,

    1. Department of Neurology, Isfahan Neurological Sciences Research Centre, Isfahan Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
    Search for more papers by this author
  • V. Shaygannejad,

    1. Department of Neurology, Isfahan Neurological Sciences Research Centre, Isfahan Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
    Search for more papers by this author
  • M. Akbari

    1. Department of Neurology, Isfahan Neurological Sciences Research Centre, Isfahan Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
    Search for more papers by this author

Fereshteh Ashtari, Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Tel.: +98 311 6700435
Fax: +98 311 6684510
e-mail: f_ashtari@med.mui.ac.ir

Abstract

Objective –  To assess the efficacy and safety of low-dose topiramate in migraine prophylaxis vs propranolol.

Patients and methods –  A randomized, double-blind, clinical trial including 62 patients with frequent migraine headaches (≥ 3 attacks per month) was performed for a period of 8 weeks. The patients were randomly divided into two treatment groups – treated by topiramate 50 mg/day and propranolol 80 mg/day, respectively. The patients were assessed at 0, 4, and 8 weeks of the study.

Results –  The topiramate group showed a reduction in the mean (±SD) of monthly migraine frequency from 6.07 (±1.89) to 1.83 (±1.39) episodes per month, headache intensity from 7.1 (±1.45) to 3.67 (±2.1) based on the Visual Analog Scale, and headache duration from 16.37 (±7.26) to 6.23 (±5.22) hours (P < 0.001). In the patients treated with propranolol, the mean (±SD) of monthly headache frequency declined from 5.83 (±1.98) to 2.2 (±1.67) per month, headache intensity lessened from 6.43 (±1.6) to 4.13 (±1.94) and headache duration decreased from 15.10 (±6.84) to 7.27 (±6.46) h (P < 0.001).

Conclusion –  This study demonstrated that both low-dose topiramate and propranolol could significantly reduce migraine headache frequency, intensity, and duration. However, compared with propranolol, low-dose topiramate showed better results.

Ancillary